US 11,667,724 B2
Anti-human CEACAM5 antibody Fab fragment
Hitoshi Doihara, Tokyo (JP); Kazunori Hirayama, Tokyo (JP); and Hiroki Shirai, Tokyo (JP)
Assigned to ASTELLAS PHARMA INC., Tokyo (JP)
Appl. No. 16/628,975
Filed by ASTELLAS PHARMA INC., Tokyo (JP)
PCT Filed Jul. 6, 2018, PCT No. PCT/JP2018/025618
§ 371(c)(1), (2) Date Jan. 6, 2020,
PCT Pub. No. WO2019/009388, PCT Pub. Date Jan. 10, 2019.
Claims priority of application No. JP2017-133698 (JP), filed on Jul. 7, 2017.
Prior Publication US 2020/0123270 A1, Apr. 23, 2020
Int. Cl. A61K 51/10 (2006.01); C07K 16/30 (2006.01); G01N 33/574 (2006.01)
CPC C07K 16/3007 (2013.01) [A61K 51/1093 (2013.01); A61K 51/1096 (2013.01); G01N 33/574 (2013.01); G01N 33/57492 (2013.01); C07K 2317/55 (2013.01)] 35 Claims
OG exemplary drawing
 
1. An anti-human CEACAM5 antibody Fab fragment selected from the group consisting of the following (a) and (b):
(a) an anti-human CEACAM5 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of an amino acid sequence from amino acid positions 1 to 121 of SEQ ID NO: 2 and a light chain comprising a light chain variable region consisting of an amino acid sequence from amino acid positions 1 to 112 of SEQ ID NO: 4; and
(b) an anti-human CEACAM5 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region derived from a heavy chain variable region consisting of an amino acid sequence from amino acid positions 1 to 121 of SEQ ID NO: 2 by the modification of glutamic acid at amino acid position 1 of SEQ ID NO: 2 into pyroglutamic acid, and a light chain comprising a light chain variable region consisting of an amino acid sequence from amino acid positions 1 to 112 of SEQ ID NO: 4.